Osgenic

Company profile

Osgenic is a physician-led technology company committed to reducing preventable surgical errors through advanced, data-driven education. By integrating medical science with cutting-edge technology, Osgenic provides a problem-focused training platform that enhances surgical decision-making and technical skills, equipping doctors with the tools to improve patient outcomes.

Unlike traditional expert-driven medical training, Osgenic’s platform leverages real-world data to create immersive, clinically relevant learning experiences. This approach enables surgeons to gain in depth understanding of critical surgical steps in a risk-free environment, helping hospitals and universities improve surgical outcomes while reducing costs associated with complications.

Osgenic holds two patents for virtual reality, which will become increasingly valuable as the company expands into VR-driven training solutions. These patents strengthen Osgenic’s technological advantage and reinforce its unique position in surgical education as the technology evolves.

Since its launch in Finland in 2022, Osgenic has gained significant traction, with over half of the country’s hospitals adopting the platform and renewing their contracts, achieving a 100% renewal rate. The international expansion in 2024 has further accelerated growth, with more than 2,000 users across 100 countries. Leading institutions such as Harvard, Johns Hopkins, and Charité are currently in trial phases, underscoring the platform’s credibility and market potential.

Co-owned by over 500 medical doctors, Osgenic is built on deep industry expertise and a commitment to advancing surgical education. This strong connection to the medical community ensures the development of high-quality solutions that seamlessly integrate into clinical practice. With increasing global adoption and growing interest from medical device companies, Osgenic is redefining surgical training and setting a new standard for safer, more effective surgery worldwide.

Company Info 

Products and services
 

The challenge: Preventable surgical errors account for nearly 4.4 million medical errors annually in the EU and contribute to over 100,000 preventable deaths in the US each year.

The solution: Osgenic offers a comprehensive digital platform designed to enhance surgical education, particularly in orthopaedics, traumatology, and related disciplines. The platform provides high-quality resources that facilitate a faster understanding of critical concepts, enabling medical professionals to improve their surgical skills and patient outcomes.

Osgenic's platform is designed to be an all-in-one resource, integrating various educational tools to support medical professionals in their continuous learning journey. 

Key features:

• Videos & steps: Users have access to high-quality videos demonstrating surgical procedures, complemented by step-by-step descriptions with images for quick review. This combination aids in visual and practical learning, ensuring a thorough grasp of each procedure.

• Pitfalls & complications: The platform highlights critical pitfalls that could lead to complications during surgery. It offers suggestions on how to avoid these issues and illustrates the connection between complications and anatomy, promoting safer surgical practices.

• Osgenic Invivo: This feature bridges the gap between theoretical anatomy and practical application. Users can explore interactive 3D anatomy within clinically relevant contexts and positions, enhancing spatial understanding and surgical precision.

• Content sharing & collaboration: Users and organizations can save notes, upload and share files, and create custom anatomy illustrations for presentations without copyright concerns. This feature enhances collaboration, strengthens peer learning, and fosters a dynamic professional network within the medical community.

Business model

Osgenic is a MedTech SaaS company transforming surgical education with an interactive, web-based training platform designed to reduce preventable surgical errors. Operating in a high-growth market, Osgenic generates revenue through hospital subscriptions and is now expanding to medical device sponsorships, and future expansion is planned into insurance companies and medical publishers.

Revenue streams

Osgenic follows a dual-revenue model:

1. Hospital subscriptions: Hospitals pay €30–€50 per user per month (VAT excluded) for access to Osgenic’s platform, integrating surgical training into their medical education programs. The company has already secured eight paying hospital customers in Finland, with additional trials underway in Finland, Germany, Switzerland and the USA. The conversion rate from a 3-month free trial to paying customer has been 80% and contract renewal rate 100%. Future expansion includes the UK, Austria, the Netherlands, Spain, Portugal and Greece.
2. Medical device sponsorships: Osgenic negotiating with leading medical device companies, offering sponsored educational content at €50,000–€150,000 per content item, with a long-term goal of transitioning to annual license fees per sponsored item.
    

Medical expertise and trusted network

Osgenic benefits from a unique company structure, with over 500 medical doctors as shareholders, creating a built-in expert review network that continuously validates and refines educational content. This structure provides:

• Credibility within the medical community, increasing adoption and trust.
• Organic referrals and endorsements, reducing reliance on paid marketing.
• Direct access to end-users, allowing Osgenic to develop solutions that align with real-world surgical workflows.

This deep connection to the medical field strengthens Osgenic’s position and makes the platform highly relevant and difficult to replicate.
 

Market expansion & competitive positioning

Osgenic’s initial focus is on orthopedic surgeons and surgeons in training, a market with 150,000 potential users. By collaborating with medical device companies that invest heavily in education and marketing, this niche alone could generate up to US$10 million in annual revenue within five years.

Since its international launch in April 2024, Osgenic has rapidly expanded to 100+ countries, with over 2,000 users from over 300 hospitals engaged globally. Leading institutions such as Harvard, Johns Hopkins, and Charité are currently in trial phases, reinforcing credibility and demand.

Revenue growth driven by medical device partnerships

While renowned hospitals are important clients, the primary growth driver for Osgenic is medical device companies. The company expects to close its first medical device sponsorship deal by summer 2025, with revenue estimates of €50,000–€150,000 per content item. Each sponsorship is tailored to a specific medical device, with content developed by Osgenic to support surgeon training and safe adoption of the device.

Osgenic is currently in discussions with multiple major medical device companies, which have shown strong interest in sponsoring content to Osgenic’s platform and integrating it into their training programs.
 

Barriers to entry & future growth

Osgenic’s unique 3D anatomy:

• Over the past 7 years Osgenic has produced unique high-quality 3D anatomy models that serve as an integral part of the product and are protected by copyright.

Osgenic holds two patents covering:

• VR-based soft tissue cutting simulation for realistic virtual surgical training.
• 3D patient-specific anatomy visualization for customized surgical planning and procedure rehearsal.

These patents strengthen Osgenic’s competitive moat, providing the possibility for expansion to the virtual reality space with unique positioning in the future.

Osgenic keeps marketing costs low by relying on LinkedIn, X (Twitter) and referrals to drive strong demand. Customer lifetime value ranges from €8,000 to €60,000, with medical device sponsorships expected to increase this significantly, reaching millions per partner.
 

Future strategy & scalability

Osgenic is expanding beyond orthopedics into general surgery, vascular surgery and urology, with international growth targeted for 2026. Future customer segments include insurance companies, which have a vested interest in reducing surgical errors. Additionally, medical publishers represent a high-potential revenue stream, with ongoing negotiations underway.

By offering a free platform for individual users and monetizing through hospitals and medical device companies, Osgenic ensures scalability, high adoption rates, and long-term profitability. With strong early traction, growing industry partnerships, and a clear path to profitability by 2025, Osgenic is well-positioned for sustained global success.

Osgenic is integrating AI-driven content scaling to enhance efficiency and reduce production costs and ensure consistency in high-quality. Unlike traditional publishing methods, this approach allows for faster scaling to different medical specialties and faster expansion of reach. 

Market

The demand for better, more effective medical and surgical training is growing rapidly as the demand and expectations of patients grow and medicine is advancing faster than ever. This leads to hospitals and medical professionals seeking safer ways to improve medical and surgical knowledge and skills.  Depending on the source, the global medical education market is valued between US$40 million and US$160 billion in 2023 and is expected to grow significantly, with projections ranging from US$80 billion to US$320 billion by 2032. This rapid expansion is driven by increasing adoption of digital learning in the medical field, which allows rightly timed knowledge transfer.

Osgenic is uniquely positioned to lead this transformation. Unlike traditional training methods that rely on 1on1 learning through a master-apprentice approach, textbooks or videos, Osgenic offers a platform that is based on real-world problem data and provides a deeper and more practical learning experience. The platform is already used in over 100 countries, with major hospitals like Harvard, Johns Hopkins, and Charité being in the trail phase of the platform.

Beyond hospitals, Osgenic has the potential to partner with medical device companies, which invest heavily in surgeon education. The orthopedic medical device market alone is expected to reach US$48 billion by 2028, with leading companies spending hundreds of millions annually on training programs. By partnering with these companies, Osgenic can scale rapidly and expand its impact on global surgical education.

With a fast-growing market, strong partnerships, and protected technology, Osgenic is in a prime position to lead the next generation of surgical and medical training. These sources collectively highlight the significant growth and potential within the surgical training and simulation market.

Management & Board

Osgenic’s leadership team brings a strong combination of medical expertise and business acumen, ensuring strategic execution and scalability.

Osgenic benefits from an experienced and strategically diverse board, bringing expertise in medical education, life sciences, digital health, and business growth. Their combined knowledge actively supports Osgenic’s expansion and long-term success.

Company structure

Osgenic Oy is a privately held company with over 1,000 shareholders, including 500+ medical doctors and a dedicated leadership team. Investors in this round invest in the main operating entity and acquire shares upon conversion. The convertible bonds will be converted into preferred shares.

Distribution of company shares

Osgenic maintains a diverse shareholder structure with strong alignment between management and investors. Arne Schlenzka, CEO of Osgenic, holds the largest individual share, ensuring leadership remains committed to long-term value creation.

Additional key shareholders include Osgenic Advisors and Icebreaker.vc. Osgenic Advisors is a consortium of over 300 medical doctors and technology experts that contribute with their expert understanding and networks when challenges are faced. Icebreaker.vc has been backing Osgenic since idea stage and has supported the company both financially and strategically to accelerate Osgenic’s growth.

Among the other shareholders are investors from two previous funding rounds, alongside investment companies, family offices, and other investment firms as minority shareholders. The success of these past funding rounds demonstrates strong public support for Osgenic’s mission.

To further strengthen commitment and motivation, Osgenic has incentivized the entire team by granting stock options to all employees, ensuring long-term dedication and alignment with the company’s success.

This balanced ownership structure fosters strategic decision-making and financial sustainability and long-term value creation.

Use of funds

The funds raised in this round will be used to accelerate Osgenic’s international expansion and and enhance its platform development. The company plans to grow its international sales team and increase hospital adoption by leveraging individual user engagement.

Osgenic is actively negotiating sponsorships with around 10 major medical device companies, particularly in orthopedics and traumatology. This funding will support the execution of these partnerships, enabling Osgenic to scale its business and strengthen its role in surgical education.

Additionally, the investment will drive AI integration, improving content creation efficiency, scalability and consistency. This ensures Osgenic continues to deliver high-quality, accessible surgical training solutions worldwide. A future expansion to virtual reality surgical simulation will be evaluated when profitability is reached.

Actual and planned figures

Get an insight into Osgenic's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Osgenic is scaling rapidly with strong hospital adoption and growing interest from medical device companies and strategic partners. With a clear path to profitability, the company is positioned for significant value growth, making it an attractive opportunity for investors seeking high-growth potential in the MedTech sector.

Bond terms & conversion events

Learn about the bond terms & conversion events in this rounds.

Investment related documents

Log in for more information.

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.